These results suggest that ESCs or ES-Exos treatment decreases both vascular and interstitial fibrosis as well as extracellular pro-fibrotic protein MMP-9 in the Dox-induced cardiomyopathy heart. The gene discussed is MMP9; the disease is cardiomyopathy.